Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
Authors
David James Pinato (ORCID: https://orcid.org/0000-0002-3529-0103)
Benjamin Adegbite (ORCID: https://orcid.org/0000-0002-2070-7965)
Maria Isabel Fiel (ORCID: https://orcid.org/0000-0002-7314-6313)
Antonio D’Alessio (ORCID: https://orcid.org/0000-0002-9164-3671)
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
David James Pinato, Benjamin Adegbite, Maria Isabel Fiel, Antonio D’Alessio et al.
Citations
54 citations
Journal
The Lancet Oncology
Topics
Hepatocellular Carcinoma Treatment and Prognosis
Field-Weighted Citation Impact (FWCI)
19.95
article
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
David James Pinato, Benjamin Adegbite, Maria Isabel Fiel, Antonio D’Alessio, Ciro Celsa, Daniel Shu, Marina Baretti, Vincent Yip, Robert Goldin, Thomas U. Marron, Yung‐Yeh Su, Alessio Cortellini, Giulia Francesca Manfredi, Chiun Hsu, Bernardo Stefanini, Mark Yarchoan, Julia Blanter, Fionnuala Crowley, Robert Anders, Stephen C. Ward, Madhava Pai, Sarah Slater, Claudia Angela Maria Fulgenzi
article en
54 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet OncologyVol. 25(11)
Institutions
Johns Hopkins University (US), Barts Health NHS Trust (GB), St Mary's Hospital (GB), Sidney Kimmel Comprehensive Cancer Center (US), Imperial College London (GB), Icahn School of Medicine at Mount Sinai (US)
Funders
Cancer Research Institute, Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi, Fibrolamellar Cancer Foundation, Boston Scientific Corporation, Regeneron Pharmaceuticals, Wellcome Trust, Exelixis, Foundation for Liver Research, Celldex Therapeutics, Atara Biotherapeutics, Incyte, NGM Biopharmaceuticals, G1 Therapeutics, Glenmark Pharmaceuticals, Cancer Research UK, National Institute for Health and Care Research, Department of Health and Social Care, Eisai, Astellas Pharma, Associazione Italiana per la Ricerca sul Cancro, Fondazione Italiana per la Ricerca sul Cancro, European Association for the Study of the Liver, Ipsen, Da Volterra, National Science and Technology Council, National Institutes of Health, Genentech, EMD Serono, Chugai Pharmaceutical, Imperial Experimental Cancer Medicine Centre, NIHR Imperial Biomedical Research Centre, National Cancer Institute